Előadók:
Prof. Dr. de Chatel Rudolf
Prof. Dr. Farsang Csaba
Prof. Dr. Parragh György
Prof. Dr. Kékes Ede
Dr. Med.habil. Barna István
Dr. Vályi Péter
Dr. Alföldi Sándor
Dr. Zámolyi Károly
Dr. Kiss István
Dr. Páll Dénes
Dr. Kancz Sándor
Dr. Nagy Viktor
Prof. Jánosi András
Dr. Sereg Mátyás
Prof. dr. Halmy László
Program, egyéb információ:
10.00-10.10 Diureticumok pro:Prof. Dr. de Chatel Rudolf
10.10-10.20 kontra: Prof. Dr. Parragh György
10.20-10.30 V I T A - KONSZENZUS
10.30-10.40 Béta blokkolók pro:Prof. Dr. Kékes Ede
10.40-10.50 kontra: Prof. Dr. Farsang Csaba
10.50-11.00 V I T A - KONSZENZUS
11.00-11.10 Centrális szerek pro:Dr. Med.habil. Barna István
11.10-11.20 kontra: Dr. Vályi Péter
11.20-11.30 V I T A - KONSZENZUS
11.30-11.40 Alfa blokkolók pro: Dr. Alföldi Sándor
11.40-11.50 kontra: Dr. Zámolyi Károly
11.50-12.00 V I T A - KONSZENZUS
12.00-12.20 K á v é s z ü n e t
12.20-12.30 Kalcium csatorna gátlók pro: Dr. Kiss István
12.30-12.40 kontra: Dr. Páll Dénes
12.40-12.50 V I T A - KONSZENZUS
12.50-13.00 ACE inhibitorok pro: Dr.Kancz Sándor
13.00-13.10 kontra: Dr. Nagy Viktor
13.10-13.20 V I T A - KONSZENZUS
13.20-13.30 ARB-k pro: Prof. Jánosi András
13.30-13.40 kontra: Dr. Sereg Mátyás
13.40-14.00 V I T A - KONSZENZUS
14.00-15.00 E b é d s z ü n e t
15.00-16.00 ABPM ART Szimpozium
Prof. dr. Halmy László: A bioellenállás (bioimpedancia) szerepe az obez-hipertónia diagnosztikájában.
Dr. Med. habil. Barna István Az ABPM és a CardioTens helye a hypertónia diagnosztikájában és gondozásában.

Neural Blockade on Cadavers
Registration: hennou.oubouaziz@optionsglobal.com

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation